November 23, 2005 -- Alexion moved almost 30% lower after its cardiovascular drug, pexelizumab, came up short in a Phase III trial; Jazz Pharma won FDA approval for Xyrem to treat daytime sleepiness among narcoleptic patients; Epix Pharma said the FDA will require another test of Vasovist, its blood-pool contrast agent, before the agency will approve the drug; Depomed and Biovail have agreed to a stand-still agreement over their Glumetza lawsuit, a once-daily extended-release formulation of metformin; and Tripos will finish its four-year project with Pfizer in December 2005, during which it received $90 million in fees. The Centient Biotech 200™ was 13 points lower at 4019.20, a decline of .32%. More details...
